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PCN37
BI OF IRESSA IN NSCLC IN THE NETHERLANDS: A HOSPITAL 
PERSPECTIVE
Langenfeld M, Scheer F
AstraZeneca BV, Zoetermeer, The Netherlands
OBJECTIVES: To gain insight in the total Costs of ﬁ rst-line treatment of NSCLC 
phase III/IV in the Dutch hospital setting. To calculate the budget impact of adding 
Iressa (geﬁ tinib), including EGFR mutation testing, to the treatment sequence. To 
identify costs of EGFR mutation testing. METHODS: A budget impact model was 
constructed by Medaxial and adapted by AstraZeneca the The Netherlands to better 
reﬂ ect the Dutch situation. The model calculates the budget impact of EGFR testing 
and the resulting therapy change for NSCLC patients in Dutch hospitals. The model 
covers the ﬁ rst-line treatment of NSCLC fase IIIb/IV patients and calculates total costs 
in a hospital setting and budget impact, taken into account the following costs—Medi-
cation—EGFR mutation testing—Administration and monitoring—Treating grade III/
IV adverse events. The model also calculates—Costs of delivery of oral therapies 
(outside hospital costs). RESULTS: Before introduction of Iressa, total costs of ﬁ rst-
line NSCLC treatment in Dutch hospitals was c41,982.936. After introduction of 
Iressa, total costs in hospital setting slightly decreased to c41.939,604 (year 1). Cost 
of EGFR mutation testing is c198,432, but medication costs of the hospital will 
decrease with c248,193. CONCLUSIONS: Adding extra diagnosis will introduce new 
costs to the NSCLC treatment. However, for an individual hospital, the extra costs 
are limited. And the total costs of ﬁ rst-line NSCLC treatment even decrease, since the 
reimbursement of Iressa is outside of the hospital budget. As a result, the hospital has 
less costs if patients are tested and the appropriate patients then treated with Iressa. 
At the moment, for some hospitals, EGFR mutation testing is still seen as a hurdle. 
Apart from the ethical point of view (making sure patients will receive the medication 
they will beneﬁ t most from), also from costs perspective, it is worth to test.
PCN38
INFLUENCE OF ME-TOOS TO POSSIBLE SAVINGS DUE TO 
BIOSIMILARS
Fuezi J, Reichardt B
Sickness Fund Burgenland, Eisenstadt, Burgenland, Austria
OBJECTIVES: To avoid the waste of market shares, me-toos of established top-selling 
biopharmaceuticals enter the market before their patent expiry. After switching the 
sales to the me-too, called “step-innovation” by the provider, the possible savings of 
biosimilars diminish as the sales are parked at the me-toos. The objective of the study 
is to analyze this hypothesis for the two2 substance classes erythropoiesis-stimulating 
agents (ESA) and granulocyte colony-stimulating factors (G-CSF). METHODS: By 
analyzing the account data of regional Austrian sickness funds, the share of prescrip-
tions of ﬁ lgrastim in GCSF (ﬁ lgrastim plus lenograstim plus pegﬁ lgrastim) and of 
epoetin in ESA (epoetin plus darbepoetin) are correlated to the costs per package. 
These data are shown for several periods, 6 months before the availability of Biosimi-
lars, 6 montha after their availability, and 2 further half-years for ESA. To take 
regional inﬂ uence into consideration, the data are shown for all nine regional sickness 
funds of Austria. RESULTS: The shares of prescription for epoetin in ESA show a 
huge regional dispersion from 42% to 88% and those of ﬁ lgrastim in GCSF from 
23% to 66%. The average costs per package have an inverse relation to their market 
share. These data are reconﬁ rmed through data of the other periods. The average costs 
per package have been declined with increased market share of the biosimilars. The 
inﬂ uence of the market share of the me-toos is though overwhelming. CONCLU-
SIONS: For pharmaceutical companies, it is a proﬁ t-maximizing strategy to substitute 
their products in time before patent expiry. The less the substitution by patent-pro-
tected alternatives succeeds, the higher the achievable cost saving potential for the 
sickness funds is.
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COST UTILITY OF HUMAN PAPILOMA VIRUS VACCINE IN SPAIN
Callejo D, Lopez-Polin A, Blasco JA
Agencia Lain Entralgo, Madrid, Spain
OBJECTIVES: It is well known that a persistent infection by human papillomavirus 
(HPV) is an essential cause of cervical cancer. Prophylactic HPV vaccines aimed at 
preventing precancerous cervical lesions and cervical cancer are currently available 
and may be used for primary prevention of cervical cancer. To deﬁ ne the efﬁ ciency 
of using HPV vaccine within a cervical cancer screening program with cytology com-
pared with the strategy of only screening with cytology. METHODS: A comprehensive 
search of studies was developed in the main electronic databases including primary 
studies assessing HPV vaccine efﬁ cacy and/or safety or HPV. Meta-analysis was 
conducted when the studies were homogeneous. a decision analysis was performed 
using a Markov model based on the results of the systematic review and information 
about the natural history of the disease (HPV infection, cervical cancer). The model 
allowed to estimate cancer incidence and associated mortality, life expectancy, and 
associated costs, with the objective of performing an economic evaluation. RESULTS: 
A total of 11 studies were included to assess HPV vaccines: seven for efﬁ cacy and 11 
for safety assessment. The efﬁ cacy of vaccine in preventing CIN2+ was 96% (95% 
CI: 91% to 98%). Modiﬁ ed intention-to-treat and intention-to-treat analyses were 
also undertaken and the results supported this trend, although efﬁ cacy was lower. The 
economic evaluation showed that the vaccination strategy would imply a cost-effec-
tiveness ratio of around c10,000 per quality-life adjusted-years (QALY). CONCLU-
SIONS: There is evidence from RCTs that the HPV vaccines are safe and effective in 
the prevention of cervical cancer precursor lesions. On top of this, this efﬁ cacy is 
reached with a reasonable cost-effectiveness ratio and within the accepable limits of 
the Spanish National Health System.
PCN40
COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE 
TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN 
PORTUGAL: A COMPARISON OF BEVACIZUMAB IN COMBINATION 
WITH INTERFERON ALFA-2A AND SUNITINIB
Silva CI1, Monteiro I2, Schwander B3
1Eurotrials Scientiﬁ c Consultants, Lisbon, Portugal; 2Roche Farmacêutica Química, Amadora, 
Portugal; 3AiM GmbH—Assessment in Medicine, Research and Consulting, Lörrach, 
Germany
OBJECTIVES: The burden of metastatic renal cell carcinoma (mRCC) is substantial 
for patients and society. Bevacizumab (BEV) combination with interferon alfa-2a 
(IFN) has demonstrated to prolong mRCC patients’ progression-free survival and to 
have comparable efﬁ cacy to sunitinib (SUN). However, tolerability differs between 
these treatment alternatives and it is therefore of importance to evaluate the economic 
impact of adverse events (AEs) management, for each alternative, in the daily clinical 
practice in Portugal. METHODS: A linear decision analytical model was applied 
considering direct medical costs only in the Portuguese Health System perspective. AEs 
incidences associated with each of the two alternatives were extracted from published 
literature. Health resource consumption was estimated based on an expert panel of 
Portuguese oncologists and urologists. Corresponding unitary costs were obtained 
through national ofﬁ cial sources. The considered time horizon was 1 year. The base-
case analysis includes all grades AEs and a normal dose (nine MUI, three times weekly) 
of IFN scenario. Deterministic univariate sensitivity analyses were performed to test 
the robustness of the model including grade 3–4 AEs analysis only and IFN low-dose 
(six MUI or three MUI, three times weekly) scenarios. RESULTS: The associated costs 
of managing AEs were considerably lower with BEV + IFN than with SUN in Portugal. 
The average treatment costs for all grade AEs per patient was c1472 for SUN and 
c1093 for BEV + IFN resulting in a difference of −379 c (a cost saving of 26% for 
BEV + IFN vs. SUN). Sensitivity analyses showed that BEV + IFN remains the less 
costly option when alternative scenarios are considered and that a low-dose IFN would 
lead even to further cost savings. CONCLUSIONS: BEV + IFN is a more tolerable 
and hence cost-saving alternative for the Portuguese Health System considering the 
AE management costs of mRCC treatment when compared to SUN. These results are 
consistent with previous evidence for other countries.
PCN41
ECONOMIC OUTCOMES AMONG 2ND LINE NON-SMALL CELL LUNG 
CANCER PATIENTS IN THE OUTPATIENT COMMUNITY SETTING
Gruschkus S1, Reyes C2, Forsyth M1, Ravelo A2, Nadler E1
1US Oncology, The Woodlands, TX, USA; 2Genentech, Inc., South San Francisco, CA, USA
OBJECTIVES: Second-line monotherapy options for advanced NSCLC include erlo-
tinib (E), docetaxel (D), or pemetrexed (P). The purpose of this retrospective study 
was to compare economic outcomes among patients (pts) receiving 2nd line mono-
therapy in the outpatient community setting. METHODS: Using US Oncology’s 
iKnowMed EMR data, we identiﬁ ed advanced NSCLC patients who received 2nd line 
monotherapy from July 1, 2006 to June 30, 2008. Economic outcomes were derived 
using outpatient claims and pharmacy data and included total outpatient, chemo-
therapy, supportive care costs, and frequency of outpatient physician visits, lab pro-
cedures, and acute care (ER/inpatient) visits. All economic outcomes were calculated 
as per-patient month (PPM) metrics over a 12-month follow-up period. Multiple 
regression analyses were used to estimate the independent association between treat-
ment (E, D, or P) on outcomes after controlling for age, gender, stage at diagnosis, 
baseline hemoglobin, and performance status. RESULTS: We identiﬁ ed 610 pts—73 
received E, 87 received D, and 450 received P. Total cost, chemotherapy costs, and 
supportive care costs differed signiﬁ cantly by treatment, as did frequency of outpatient 
visits and lab procedures. Relative to P, total adjusted costs PPM is $1579 lower for 
D and $1584 lower for E (P < 0.05). Majority of the cost savings are due to decreased 
chemo-related costs. Outpatient visits, lab procedures, and acute care visits are also 
less frequent with E relative to P (−2.6 PPM, P < 0.05). CONCLUSIONS: In US 
outpatient setting, pts receiving E and D have statistically signiﬁ cant lower costs and 
resource use relative to pts receiving P.
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COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY 
FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO: 
BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A 
COMPARED WITH SUNITINIB
Carlos F, Ramirez J, Aguirre A
R a C Salud Consultores S.A. de C.V., México, D.F., Mexico
OBJECTIVES: Bevacizumab plus interferon-α2a (BEV+IFN) prolongs progression-
free survival (PFS) to >10 months, providing comparable efﬁ cacy to sunitinib in 
patients with metastatic renal cell carcinoma (mRCC). However, the type and fre-
quency of adverse events (AE) differ between these two regimens. We aimed to assess 
the costs of managing AE of grade 3/4 of these regimens from the perspective of public 
health-care system in Mexico. METHODS: A linear decision analytic model was 
developed to compare the direct medical costs of managing AE of grade 3/4 of BEV 
+ IFN and sunitinib in patients with mRCC. AE of grade 1/2 are assumed to entail 
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very low costs or even no medical attention, and therefore were not taken into account. 
Data sources included the published incidence rates for the 25 most frequent AE in 
controlled clinical trials with BEV + IFN or sunitinib. a panel integrated by 10 local 
experts from different specialties was constituted to estimate medical and nonmedical 
resource use for diagnosis and treatment of each AE grade 3/4. Cost of medications 
involved in treating AE were taken from public bids and unit cost of medical services 
(outpatient medical consultations, laboratory and image tests, hospitalization at 
general ward and at intensive care unit, surgical and nonsurgical procedures, etc.) was 
gathered from ofﬁ cial tariff lists. All costs are expressed in 2009 Mexican pesos 
(MXN). RESULTS: The average cost per patient for the management of grade 3/4 AE 
were 76.5% higher for sunitinib ($17,577) than those for BEV + IFN ($9959). The 
main cost drivers for sunitinib were hypertension, heart failure, and non-febrile neu-
tropenia; for BEV + IFN, main cost drivers included proteinuria and arterial and 
venous thromboembolic events. CONCLUSIONS: BEV + IFN has a more tolerable 
AE proﬁ le when compared to sunitinib, which is also reﬂ ected in the nearly double 
cost for managing AE with sunitinib in patients with mRCC.
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COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE 
FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH 
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG 
CANCER IN ITALY
Ravera S1, Walzer S2, Ray J2
1Roche S.p.A., Milano, Italy; 2F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: First-line chemotherapy for locally advanced or metastatic non-small 
cell lung cancer (mNSCLC) is usually limited to four to six cycles, as prolonged 
exposure leads to cumulative toxicity without additional survival beneﬁ t. Maintenance 
therapy represents a new treatment option which can delay disease progression and 
extend survival in patients with mNSCLC. Erlotinib and pemetrexed are currently the 
only treatments speciﬁ cally approved for this indication by the European Medicines 
Agency and US Food and Drug Administration; therefore, it is important to compare 
the monthly treatment costs of using erlotinib or pemetrexed for the maintenance 
therapy of patients with mNSCLC. METHODS: Italian monthly treatment costs were 
calculated as the sum of the ex-factory costs for the average dose (erlotinib = 150 mg/
day, pemetrexed = 500 mg/m2) over a 30-day treatment duration plus administration 
costs. Monthly administration costs were derived from regional tariffs for oncology 
drugs. RESULTS: Monthly drug costs for erlotinib maintenance therapy are lower 
than for pemetrexed (c1517 vs. c2770, respectively). In addition, as an intravenous 
treatment, pemetrexed is associated with additional costs related to administration 
(estimated at c140 per month), whereas orally administered erlotinib is not associated 
with any administration costs. Pemetrexed total monthly treatment costs are therefore 
c2910, c1393 higher than erlotinib total monthly treatment costs. The cost saving 
associated with erlotinib would allow approximately 92% more patients to be treated 
with erlotinib maintenance therapy, based on a ﬁ xed health-care budget. Furthermore, 
it is anticipated that the management of pemetrexed-related adverse events (e.g., 
neutropenia, anaemia) would be more costly than those related to erlotinib use (e.g., 
rash, pruritus). Therefore, the cost saving when using erlotinib versus pemetrexed for 
ﬁ rst-line maintenance therapy may be greater in a real-world setting. CONCLU-
SIONS: Based on Italian costs, erlotinib is a cost-saving treatment option compared 
with pemetrexed, for the ﬁ rst-line maintenance therapy of patients with locally 
advanced or mNSCLC.
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COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE 
FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH 
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG 
CANCER IN SPAIN
Castro de Carpeño J1, Castro-Gómez AJ2, Walzer S3, Ray J3
1La Paz University Hospital, Madrid, Spain; 2Roche Farma, Madrid, Spain; 3F. Hoffmann-La 
Roche Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: First-line chemotherapy for locally advanced or metastatic non-small 
cell lung cancer (mNSCLC) is usually limited to four to six cycles, as prolonged 
exposure leads to cumulative toxicity without additional survival beneﬁ t. Maintenance 
therapy represents a new treatment option which can delay disease progression and 
extend survival in patients with mNSCLC. Erlotinib and pemetrexed are currently the 
only treatments speciﬁ cally approved for this indication by the European Medicines 
Agency and US Food and Drug Administration; therefore, it is important to compare 
the monthly treatment costs of using erlotinib or pemetrexed for the maintenance 
therapy of patients with mNSCLC. METHODS: Spanish monthly treatment costs 
were calculated as the sum of the ex-factory costs for the average dose (erlotinib = 
150 mg/day, pemetrexed = 500 mg/m2) over a 30-day treatment duration plus admin-
istration costs. Monthly administration costs were obtained from regional tariffs 
(Galician Health Service). RESULTS: Monthly drug costs for erlotinib maintenance 
therapy are lower than for pemetrexed (c2045 vs. c2914, respectively). In addition, 
as an intravenous treatment, pemetrexed is associated with additional costs related to 
administration (estimated at c235 per month), whereas orally administered erlotinib 
is not associated with any administration costs. Pemetrexed total monthly treatment 
costs are therefore c3149, c1104 higher than erlotinib total monthly treatment costs. 
The cost saving associated with erlotinib would allow approximately 54% more 
patients to be treated with erlotinib maintenance therapy, based on a ﬁ xed health-care 
budget. Furthermore, it is anticipated that the management of pemetrexed-related 
adverse events (e.g., neutropenia, anaemia) would be more costly than those related 
to erlotinib use (e.g., rash, pruritus). Therefore, the cost saving when using erlotinib 
versus pemetrexed for ﬁ rst-line maintenance therapy may be greater in a real-world 
setting. CONCLUSIONS: Based on Spanish costs, erlotinib is a cost-saving treatment 
option compared with pemetrexed, for the ﬁ rst-line maintenance therapy of patients 
with locally advanced or mNSCLC.
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DIFFERENCES IN HEALTH-CARE COSTS FOR PATIENTS WITH 
CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED BY 
ONCOLOGISTS OR UROLOGISTS
Engel-Nitz NM1, Alemayehu B2, Nathan F2, Parry D3, Kulakodlu M1
1i3 Innovus, Eden Prairie, MN, USA; 2AstraZeneca, Wilmington, DE, USA; 3AstraZeneca, 
Macclesﬁ eld, Cheshire, UK
OBJECTIVES: Patients with CRPC may be treated by urologists or oncologists. This 
study examined differences in total health-care costs and prostate cancer-speciﬁ c costs 
in patients treated by oncologists or urologists. METHODS: A retrospective study 
design used medical and pharmacy claims (2001–2007) to identify patients with CRPC 
from a large US-managed care health plan. Patients were stratiﬁ ed based on the spe-
cialist providing treatment following castration; an oncologist (with/without a urolo-
gist, ONC), and a urologist without an oncologist (URO). A 6-month baseline period 
was used to assess patient characteristics and initial clinical status; a variable follow-up 
period (until disenrollment or December 31, 2008) was used to assess total health-care 
costs. Lin’s regression was used to assess costs adjusting for the variable follow-up 
and patient and treatment characteristics. RESULTS: A total of 995 URO and 1590 
ONC patients with CRPC were identiﬁ ed. Mean age was higher in URO patients than 
in ONC patients (75.5 vs. 71.1 years, P < 0.001). The URO cohort had a lower average 
Charlson comorbidity score (3.7 vs. 4.9, P < 0.001), fewer comorbid illnesses (10.1 vs. 
11.1, P < 0.001), and were less likely to have other cancers (17.7% vs. 27.4%, P < 
0.001) or to have had hormones, chemotherapy, and radiation treatment during the 
baseline period. After multivariate adjustment, mean total health-care costs during the 
ﬁ rst year were $31,792 (URO), $54,306 (ONC with chemotherapy, P < 0.05), and 
$30,894 (ONC without chemotherapy); during 6 years of follow-up, cumulative costs 
rose to $86,706 (URO), $168,794 (ONC with chemotherapy), and $114,180 (ONC 
without chemotherapy), P < 0.05 for all. a similar pattern was observed for prostate 
cancer-speciﬁ c cumulative costs. CONCLUSIONS: CRPC patients treated by oncolo-
gists, particularly patients with chemotherapy, had higher total and prostate cancer-
related health-care costs than patients treated by urologists.
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ECONOMIC EVALUATION OF ONCOTYPE DX® TO TARGET 
CHEMOTHERAPY USE IN LYMPH-NODE–NEGATIVE, OESTROGEN-
RECEPTOR–POSITIVE, EARLY-STAGE BREAST CANCER IN IRELAND
Lacey L1, Hornberger J2
1Lacey Solutions Ltd., Skerries, Ireland; 2Stanford University & Cedar Associates, Menlo Park, 
CA, USA
OBJECTIVES: Oncotype DX® is a clinically validated assay used to guide chemo-
therapy decision-making for patients with early-stage breast cancer. Patients classiﬁ ed 
as low risk by Oncotype DX® have low likelihood of beneﬁ tting from chemotherapy. 
By foregoing chemotherapy, patients avoid the risk of chemotherapy-related toxicities. 
For those patients reclassiﬁ ed by Oncotype DX® as high risk, the assay identiﬁ es 
patients who are likely to gain a large beneﬁ t from chemotherapy. The study objective 
was to estimate the health-care costs of using Oncotype DX® testing in early-stage, 
lymph node-negative breast cancer in Ireland. METHODS: A cost-analysis estimated 
the health-care costs (chemotherapy, administration, adverse events [AEs], and G-CSF 
costs) in patients whose treatment decisions are informed by Oncotype DX® testing. 
The perspective was that of the Irish health-care system. The chemotherapy regimen 
was docetaxel and cyclophosphamide (4 × 21-day cycles), costing approximately 
c9200. Univariate sensitivity analysis was performed, together with a probabilistic 
sensitivity analysis (PSA) of the net reduction in chemotherapy usage from Oncotype 
DX® testing. In a meta-analysis of seven published studies, there was an estimated 
30% (95% CI −40%, −21%; P = 0.0003) absolute reduction in chemotherapy usage 
after Oncotype DX® testing (ratio 0.49 [95% CI 0.41, 0.58]; P < 0.00001). RESULTS: 
Adoption of Oncotype DX® testing resulted in approximate cost-neutrality (0.4% 
increase in cost) to the Irish health-care system, under the above conditions. The main 
cost drivers were: net reduction in chemotherapy usage from Oncotype DX® testing 
and the rate of G-CSF usage. From the PSA, the probability of Oncotype DX® being 
cost-saving is approximately 47%. CONCLUSIONS: Using Oncotype DX® to inform 
chemotherapy decisions in early-stage breast cancer has the potential to reduce the 
incidence of chemotherapy-induced AEs, while being approximately cost-neutral to 
the Irish health-care system. a cost-effectiveness analysis would be expected to result 
in a low incremental cost-effectiveness ratio.
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CHANGE OF ANTIFUNGAL TREATMENT PATTERNS AND ASSOCIATED 
COSTS IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) 
AFTER CHEMOTHERAPY IN A GERMAN HOSPITAL FROM 2004 TO 2006
Boehme A1, Atta J1, Mousset S1, Steffen B1, Serve H1, Hoelzer D1, Shlaen R2, Ehlken B2, 
Bug G1
1Med. Clinic II, J.W. Goethe-University, Frankfurt, Germany; 2IMS Health, Munich, Germany
OBJECTIVES: To describe changes in outcomes, treatment patterns and costs of the 
management of hospitalized patients with acute AML after chemotherapy in Germany 
